 PETACH TIKVA, Israel--BUSINESS WIRE--- CANF--Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has received clearance from the Israeli Ministry of Health to commence a Phase IIb study of its drug candidate Namodenoson in the treatment of NASH. Can-Fite expects to commence enrollment in Q3 2021, ahead of the prior expected start date of Q4 2 